Evaluation of the Binding of Radiolabeled Rituximab to CD20-Positive Lymphoma Cells: An In Vitro Feasibility Study Concerning Low-Dose-Rate Radioimmunotherapy with the alpha -Emitter super(227)Th
Radioimmunotherapy (RIT) with the alpha-emitter super(227)Th is currently under evaluation. super(227)Th is conjugated to the chimeric anti-CD20 monoclonal antibody rituximab, using the chelator p-isothiocyanato-benzyl-DOTA. In this study, the binding of super(227)Th-DOTA-p-benzyl-rituximab to three...
Saved in:
Published in | Cancer biotherapy & radiopharmaceuticals Vol. 22; no. 4; pp. 469 - 479 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
01.08.2007
|
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!